Navigation Links
Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2013 Financial Results
Date:11/7/2013

gulatory decisions and Arena's business prospects; government and commercial reimbursement and pricing decisions; the entry into or modification or termination of collaborative arrangements; unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to any of Arena's research and development may not meet regulatory requirements or otherwise be sufficient for further research and development, regulatory review or approval or continued marketing; Arena's ability to obtain and defend patents; the timing, success and cost of Arena's research and development; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; and satisfactory resolution of litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Contact: Arena Pharmaceuticals, Inc.

Media Contact: Russo PartnersCindy McGee, Vice President,
Investor Relations & Alliance Management
cmcgee@arenapharm.com
858.453.7200, ext. 1479

David Schull, President

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, November 7
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch Global Healthcare Conference
4. Arena Pharmaceuticals Completes Phase 1b Clinical Trial Evaluating APD811 for Pulmonary Arterial Hypertension
5. Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2013 Financial Results
6. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, August 1
7. Arena Pharmaceuticals to Present at the 2013 Wells Fargo Securities Healthcare Conference
8. Former Semi-Pro Arena Football Player Bridged to Heart Transplant with the SynCardia Total Artificial Heart
9. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
10. BIOCOM Applauds Arena Pharmaceuticals Commitment to Innovation, Contributions to Southern California Life Science Community
11. Carena Launches 24/7 Virtual Care Delivery Service for Hospital Systems and Primary Care Clinics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  Publicis Groupe customer ... , Managing Partner and Healthcare Industry Group Leader, has ... which recognizes the most inspiring people in the life-sciences ... in research and development, marketing, technology, creativity, strategy and ... 2006 as a partner in its leading Rosetta Consulting ...
(Date:8/21/2014)... 2014 /CNW/ - Eisai Limited is pleased to support the ... comic book available in Canada . The ... to educate children and their parents about epilepsy, the most ... more than 300,000 Canadians. Eisai is guided by a corporate ... which the patient is central – there was a need ...
(Date:8/21/2014)... Aug. 21, 2014 /CNW/ - The Canadian Epilepsy Alliance (CEA) ... series designed to educate children about the most common neurological ... Medikidz Explain Epilepsy comic series tells a fictional story ... middle school while living with epilepsy. "Despite ... is still so much misinformation and lack of awareness out ...
Breaking Medicine Technology:Shannon Hartley Shines in PharmaVOICE 100 2Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2Action Heroes Harness Powers to Educate Children About Epilepsy 2Action Heroes Harness Powers to Educate Children About Epilepsy 3
... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ... Administration (FDA) has accepted for review the Company,s supplemental ... Use for the prevention of gout flares in patients ... Fee Act (PDUFA), the goal for a standard review ...
... CITY, Nev., Nov. 22, 2011   Denali Concrete Management ... November 21, 2011 of the reverse acquisition of Denali ... of which Denali acquired all the outstanding shares of ... has been granted from Can-Fite an exclusive license over ...
Cached Medicine Technology:Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 2Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 3Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 4Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 5Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 6Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 7Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 8Denali Concrete Management Inc. Announces its Acquisition of CF101 for Ophthalmic Indications and the Completion of Above $6 Million Private Placement at $1.144 Per Share 2Denali Concrete Management Inc. Announces its Acquisition of CF101 for Ophthalmic Indications and the Completion of Above $6 Million Private Placement at $1.144 Per Share 3
(Date:8/21/2014)... (PRWEB) August 21, 2014 CarePoint ... Radiologists, Amish P. Patel, MD, and Sujoy Menon, ... welcomes Dr. Patel and Dr. Menon to the ... array of diagnostic imaging services to patients in ... Medical Center, Christ Hospital and Hoboken University Medical ...
(Date:8/21/2014)... 21, 2014Popular fiction that normalizes and glamorizes violence against ... be associated with a greater risk of potentially harmful ... new study are presented in the article " Fiction ... in Adolescent and Young Adult Females ," published in ... from Mary Ann Liebert, Inc., publishers . The ...
(Date:8/21/2014)... have developed a genetically engineered line of mice that ... on epilepsy, Alzheimer,s and other diseases. , The ... of fluorescence in response to different calcium levels. This ... and microglia, to be studied in a new way. ... how the brain works," said Petr Tvrdik, Ph.D., ...
(Date:8/21/2014)... August, 21, 2014 Young girls with an ... may be at increased risk of developing urinary tract ... Baptist Medical Center. The treatment may be as simple ... bubble baths and swimming pools. , "Vulvitis is a ... said senior author Steve J. Hodges, M.D., associate professor ...
(Date:8/21/2014)... with schizophrenia often have trouble engaging in daily tasks ... from San Francisco State University suggests the reason might ... required to complete tasks. , The research, detailed in ... of Abnormal Psychology , can assist health professionals in ... those patients function normally by breaking up larger, complex ...
Breaking Medicine News(10 mins):Health News:Two Top Radiologists Join CarePoint Health 2Health News:Women's health and Fifty Shades: Increased risks for young adult readers? 2Health News:Mouse model for epilepsy, Alzheimer's gives window into the working brain 2Health News:Researchers identify potential risk factors for urinary tract infections in young girls 2Health News:Difficulty assessing effort drives motivation deficits in schizophrenia, study finds 2
... 24 NHS Choices ( http://www.nhs.uk ), the,digital ... well guide on women,s,health aged 18-39 aimed at ... lifestyle., Based on NHS accredited information, the ... with information about,walking to get healthy, looking after ...
... June 24 TransUnion announced today a ... cycle workflow and,financial analytics product suite -- ... Institute (ANI) Healthcare Financing Conference. Revenue,Manager is ... real time,patient eligibility for financial assistance at ...
... LOS ANGELES, June 24 Anti-Doping Research,Inc. (ADR), one ... performance-enhancing drugs in sport, is pleased to announce that ... "We,ve been up and running and fully-operational for a ... Officer of the organization. "But,now it,s all official and ...
... Inc. (Pink Sheets: AMHI), http://www.americanhealthchoice.com, a medical ... today, in an update for Company,shareholders, said its ... 31, 2008,totaled $32,300., Net income for the ... Company announced that patient billings from its four ...
... To, Implement Electronic Bill / Payment Solutions Before Minnesota,s ... ... and CONCORD, Calif., June 24 More than one,hundred auto insurance ... Mitchell Medical,s 2008 Industry,Conference held March 17-19 in Monterey, CA were ...
... in Generic Market Information Offers Newport Horizon ... ... SHANGHAI, China, June 24 /Xinhua-PRNewswire/ -- Thomson Reuters, the,world,s leading ... CPhI China 2008(1) the release of Newport,Horizon Premium, designed specifically ...
Cached Medicine News:Health News:TransUnion's Enhanced Revenue Manager(SM) Improves Patient Financial Assistance, Assessments and Hospital Productivity 2Health News:TransUnion's Enhanced Revenue Manager(SM) Improves Patient Financial Assistance, Assessments and Hospital Productivity 3Health News:TransUnion's Enhanced Revenue Manager(SM) Improves Patient Financial Assistance, Assessments and Hospital Productivity 4Health News:Leading Performance-Enhancing Drug Research Institute Anti-Doping Research (ADR) Establishes Nonprofit Status 2Health News:American HealthChoice CEO Dr. J.W. Stucki Provides Company Update 2Health News:2008 Mitchell Medical Industry Conference Previews 100 Percent Paperless Auto Medical Claim Solution 2Health News:2008 Mitchell Medical Industry Conference Previews 100 Percent Paperless Auto Medical Claim Solution 3Health News:2008 Mitchell Medical Industry Conference Previews 100 Percent Paperless Auto Medical Claim Solution 4Health News:Thomson Reuters Introduces a New Solution to Boost Competitive Advantage in China's Generics and API Market 2Health News:Thomson Reuters Introduces a New Solution to Boost Competitive Advantage in China's Generics and API Market 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: